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Background: The role of ductular reaction (DR) in hepatocellular carcinoma (HCC) remains to be elucidated.
Methods: In this study, we tried to uncover possible effect by correlating peritumoral DR in a necroinflammatory
microenvironment with postoperative prognosis in HCC. The expression of peritumoral DR/CK19 by
immunohistochemistry, necroinflammation and fibrosis were assessed from 106 patients receiving curative resection
for HCC. Prognostic values for these and other clinicopathologic factors were evaluated.
Results: Peritumoral DR significantly correlated with necroinflammation (r = 0.563, p = 3.4E-10), fibrosis (r = 0.435,
p = 3.1E-06), AFP level (p = 0.010), HBsAg (p = 4.9E-4), BCLC stage (p = 0.003), TNM stage (p = 0.002), multiple nodules
(p = 0.004), absence of tumor capsule (p = 0.027), severe microscopic vascular invasion (p = 0.031) and early
recurrence (p = 0.010). Increased DR was significantly associated with decreased RFS/OS (p = 4.8E-04 and p = 2.6E-05,
respectively) in univariate analysis and were identified as an independent prognostic factor (HR = 2.380, 95%
CI = 1.250-4.534, p = 0.008 for RFS; HR = 4.294, 95% CI = 2.255-8.177, p = 9.3E-6 for OS) in multivariate analysis.
Conclusions: These results suggested that peritumoral DR in a necroinflammatory microenvironment was a poor
prognostic factor for HCC after resection.
Keywords: Ductular reaction (DR), Hepatic progenitor cells (HPCs), Necroinflammation, Fibrosis, Hepatocellular
carcinoma (HCC), PrognosisBackground
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide [1]. Despite the great advance-
ment in diagnosis and treatment modalities, especially
surgical and targeted therapies, it’s outcome remains
challenging due to frequent recurrence [2]. It is short of
effective specific treatment after postoperative metastasis
and recurrence in HCC [3]. Therefore, it is of great* Correspondence: jiameiyang@gmail.com; weilixin@yahoo.com
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stated.importance to seek optimal biomarkers that help predict
early recurrence or metastasis.
HCC with progenitor cell features, possibly reflecting a
progenitor cell origin, has a very bad prognosis [4].
Hepatic progenitor cells (HPCs) exhibit large nuclear-
cytoplasmic ratio and oval-shaped nucleus, known as oval
cells in rodents [5]. It is believed that HPCs are the de-
scendants of stem cells. HPCs are scarce in the healthy
liver, but upon stimulation, cells resident in the Canals of
Hering proliferate across the hepatic lobule infiltrating the
liver parenchyma [6]. HPCs can be observed by immuno-
histochemistry and electron microscope. The neoplastic
cells are offspring of HPCs and each can differentiate a lit-
tle differently, according to the local microenvironment in
each part of the tumor if it explains the enormous pheno-
typic heterogeneity of a neoplasm [4]. In immunohisto-
chemistry the phenotypes of HPCs express as OV6, CK7,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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be able to differentiate into both hepatocytes and cho-
langiocytes when the latter fails to respond after severe
injury [10].
HPCs form ductular reaction (DR), emanating from
the portal zone and expanding into the parenchyma
when they are activated to proliferate/differentiate, hepa-
tocytic differentiation of these cells leads to the forma-
tion of intermediate hepatocytes [5]. Three types of DR
are classically recognized, type 1, proliferation of pre-
existing ducts and ductules; type 2, ductular metaplasia
of hepatocytes and type 3, activation/proliferation of
HPCs [11]. DR can be marked by immunostained with
CK7 and CK19 [12,13]. DR plays an important role in
hepatocellular or cholangiocellular proliferation after
virus related inflammation and damage. DR may repre-
sent a protective mechanism that allows intrahepatic
cycling of bile acids to occur in chronic ductopenic bil-
iary diseases [13]. Its immunostaining may help to iden-
tify small foci of invasion and to distinguish noninvasive,
high-grade dysplastic nodules from both minimally inva-
sive and overtly invasive HCC [12].
Activated and proliferative mechanism of HPCs is not
clear, and inflammatory cytokine is considered as a key
role in animal experiment [14]. Severity and location of
inflammatory infiltration associated with activity and lo-
cation of HPCs in chronic virus hepatitis [15]. Inflamma-
tion has emerged as the seventh hallmark of cancer [16].
Such prolonged self-replication in an inflammatory micro-
environment could result in the accumulation of genetic
lesions that cause cancer formation [17]. There is substan-
tial evidence that the proinflammatory response at the
tumor stroma could be rerouted into a tumor-promoting
direction by stimulating angiogenesis and tissue remodel-
ing [18].
However, the role of peritumoral DR in a necroin-
flammatory microenvironment remains to be elucidated
in HCC. At the present study, we investigated DR and
necroinflammatory microenvironment of patients with
HCC. We also tried to uncover possible effect by cor-
relating DR in a necroinflammatory microenvironment
with postoperative prognosis in HCC.
Methods
Patients and specimens
106 patients received curative resection of HCC in East-
ern Hepatobiliary Hospital, the Second Military Medical
University between 2001 and 2003. The total number of
the patients with resected tumors during the same time
period was 2180. Patients did not have signs of distant
metastasis nor had they received anticancer therapy be-
fore surgery. The pathology of each patient was con-
firmed. Liver function was assigned by Child-Pugh
scoring system. The role of the child pugh score was that2 patients were B and 104 patients were A in this study.
The tumor stage was determined according to 2002
AJCC/UICC tumor-node-metastasis (TNM) classification
system and the Barcelona-Clinic Liver Cancer (BCLC) sta-
ging classification. Follow-up was as described in our pre-
vious report [1]. Data was censored at the last follow-up
for patients without recurrence or death. Recurrence-free
survival time (RFS) and overall survival time (OS) was
defined as the interval between the time of surgery to that
of recurrence or death, respectively. All human sample
collection procedures were approved by China Ethical
Review Committee and informed consent was obtained
from all participants.
H&E and immunohistochemistry
The paraffin-embedded tissues stained with H&E were
scored in a blinded manner according to Ishak scoring
system by a single pathologist. The degree of necroin-
flammatory activity and the stage of fibrosis were scored
0–18 or 0–6 respectively in the non-tumor specimen ac-
cording to Ishak et al. [19]. Median values were used as
a cut-off in subsequent analyses. Immunohistochemistry
was carried out according to appropriate protocols [20].
The primary antibody used was mouse monoclonal anti-
CK19 (1:100, clone RCK108, Dako), Blank controls were
treated identically except that the primary antibodies
were omitted.
Evaluation of DR and morphometric determinations
CK19-immunoreactive DR was analyzed at the epithelial-
stromal boundaries at the outer edge of tumor. Peritumoral
DR was semiquantified as follows: 0 = none, 1 = <10%, 2 =
10% to 25%, 3 = 26% to 50%, and 4 = >50% [12]. Median
value was used as a cut-off in subsequent analyses. HPCs
and intermediate hepatobiliary cells were considered as
CK19-positive cells, previous finding showing that [5].
Tissue samples
The study was approved by the Committee on Ethics, the
Eastern Hepatobiliary Surgery Hospital of the Second
Military Medical University, informed consent which has
been conducted according to the principles expressed in
the Declaration of Helsinki was obtained from each pa-
tient. All participants provided their written informed
consent to participate in this study. HCC tissues were ob-
tained from patients who underwent surgical operations
for the tumors at Eastern Hepatobiliary Surgery Hospital.
Statistical analyses
Correlations between immunostaining parameters and
clinicopathologic features were analyzed by χ2 tests, the
Fisher’s exact test, and Spearman’s rho coefficient test as
appropriate. Univariate and multivariate analysis was
carried out with the Kaplan-Meier method and the Cox
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pared with the log-rank test. For each analysis, only
p <0.05 (two-sided) was considered statistically signifi-
cant. All statistical analyses were made by use of SPSS
12.0 (SPSS Inc., Chicago, IL, USA).
Results
H&E and immunohistochemical characteristics
Representative images of necroinflammation and fibrosis/
cirrhosis are shown (Figure 1). DR is shown in Figures 1, 2
and 3. As shown in Table 1, DR significantly correlated
with necroinflammatory grade (r = 0.563, p = 3.4E-10)
and fibrotic stage (r = 0.435, p = 3.1E-06). HPCs, inter-
mediate hepatocytes and correlations with DR are shown
in Figures 2 and 3.
Correlations between DR and clinicopathologic features
As shown in Table 2, increased DR correlated with ad-
vanced BCLC stage (p = 0.003), TNM stage (p = 0.002),
with elevated serum ALT (p = 0.017), ALP (p = 0.007),
AFP (p = 0.010) and HBsAg (+) (p = 4.9E-4). Increased
DR was also tended to correlate with multiple nodules
(p = 0.004), absence of tumor capsule (p = 0.027), severe
microscopic vascular invasion (p = 0.031) and early re-
currence (p = 0.010).
Prognostic factors
The follow-up was completed on December 25, 2009, with
median follow-up time of 93 months (75 to 107 months).
The 1-, 3-, 5-, 7-year RFS and OS rates were 54.7%, 24.5%,
19.8%, 8.5% and 71.7%, 36.8%, 32.1%, 20.8% respectively.
In the univariate analysis, decreased DR (p = 2.6E-05
for OS and p = 4.8E-04 for RFS, Figure 4A and B), de-
creased necroflammation (p = 0.001 for OS and p = 0.003
for RFS, Figure 4C and D) and decreased DR with lower
necroflammation (p = 6.1E-05 for OS and p = 0.001 for
RFS, Figure 4E and F) were associated with prolongedFigure 1 Immunostaining of DR, histopathology of necroinflammatio
steatosis (thin arrows) and focal necrosis (thick arrows) were shown in the
shown. (D) Fibrosis/cirrhosis and portal inflammation were shown. (E) Incre
DR was around a nodule in the peritumoral tissue. (G) DR and necroinflam
necrosis were nearby DR. Inflammatory cells were around DR in the portal
cirrhotic nodule. (A and G 200×; C 400×; B, D, E, F and H 100×).RFS and OS. Other clinicopathologic factors significant
for RFS/OS are shown in Table 3.
Factors demonstrated to be significant in univariate
analysis were then used into the Cox proportional haz-
ards regression model for multivariate analysis. Both DR
and tumor size were independent prognostic factors for
RFS and OS. DR was associated with elevated risks of re-
currence (HR = 2.380, 95% CI = 1.250-4.534, p = 0.008)
and death (HR = 4.294, 95% CI = 2.255-8.177, p = 9.3E-06).
Tumor size was associated with elevated risks of recur-
rence (HR = 1.804, 95% CI = 1.057-3.080, p = 0.031) and
death (HR = 2.950, 95% CI = 1.694-5.137, p = 1.3E-04). Be-
sides, TNM and necroinflammatory grade were demon-
strated as independent predictors for RFS; while BCLC
stage was independent prognostic factors for OS.
There are two types of recurrence for HCC, one is
early recurrence (true metastasis, ≤2 years after surgery)
and the other is late recurrence (de novo cancer, >2 years
after surgery) [21]. A total of 81/106 (76.4%) patients
suffered from tumor recurrence, of whom 60/81 (74.1%)
patients recurred within two years and 21/81 (26.0%) re-
curred more than two years after surgery. As shown in
Table 2, patients with high DR were more likely to suffer
from early recurrence compared with the low subgroup
(8/52 vs 9/12, p = 0.010).
Discussion
To the best of our knowledge, this is the first study to
identify peritumoral DR as an independent prognostic
factor for HCC after resection. Patients with decreased
peritumoral DR had a significantly prolonged OS and
RFS compared with the increased subgroup. Therefore,
patients with high peritumoral DR require closer follow-
up after surgery, and peritumoral DR could also serve as
a new biomarker predicting HCC recurrence.
DR occurs in cholestatic diseases, in inflammatory dis-
eases and in conditions with massive loss of parenchyman and fibrosis/cirrhosis. (A, C) Ballooning degeneration (arrowheads),
peritumoral parenchyma. (B) Cirrhosis and interface hepatitis were
ased DR was around a nodule in the peritumoral tissue. (F) Decreased
mation were shown. Ballooning degeneration, steatosis and focal
tracts. (H) DR and cirrhosis were shown. DR was at the periphery of a
Figure 2 Immunostaining of DR, histopathology of HPCs and intermediate hepatocytes in fibrotic tissue or peritumoral and tumoral
tissues. (A, B, C) DR emanated from the portal zone and expanded into the parenchyma of proliferative nodules, HPCs (arrowheads) and
intermediate hepatocytes (arrows) can be seen in the nodules. (D, E, F) DR and CK-19 positive tumor (in dashed line) that had no capsule were
shown. HPC (arrowhead) was close to DR, intermediate hepatocytes (arrows) were between DR and neoplastic nodule. (A and D 100×; B and
E 200×; C and F 400×).
Figure 3 Correlations of DR with HPCs and intermediate
hepatocytes in the peritumoral and tumoral tissues. (A) DR was
at the periphery of the portal tracts. CK-19 positive tumor (in dashed
line) had a partial capsule. A lot of intermediate hepatocytes were
diffused in the peritumoral parenchyma. (B) At the tumoral borderline,
2 or 5 HPCs (arrowheads) gathered tightly, one intermediate hepato-
cyte (arrow) was among them. (C) In the peritumoral tissue, several
intermediate hepatocytes (arrows) were nearby DR that was at the
periphery of the portal tracts, and HPC (arrowhead) was in DR.
(D) At the tumoral borderline, HPCs (arrowheads) gathered
together, one intermediate hepatocyte (arrow) was closed to
them, while intermediate hepatocytes (arrows) were diffused in
the tumoral parenchyma. (A 100×; B, C and D 400×).
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nized [11]. We precluded the DR which originated from
bile ducts obstructive diseases or cholestatic parenchymal
damage in 106 patients with HCC, so the DR we observed
could represent an activation of HPCs. Intermediate hepa-
tobiliary cells of several differentiation states are continu-
ously being produced in a dynamic nature of DR [25].
These data are supported by our results (Figures 2 and 3).
DR is thought to arise due to a complex interaction be-
tween hepatocytes, hepatic progenitor cells, hepatic stel-
late cells and extracellular matrix as well as inflammatory
cells and endothelial cells [13]. The total necroinflamma-
tory score was significantly associated with the expansion
of DR (Table 1). The result is in agreement with recent
findings [26]. There was a highly significant correlation
between the area of DR and fibrotic stage [27]. It may be
important in the development of fibrosis [28]. These data
are supported by our result showing that DR was signifi-
cantly correlated with fibrotic stage (Table 1). Insulin re-
sistance and hepatic inflammation might cause liver
fibrosis by the expansion of the DR and the occurrence of
epithelial-mesenchymal transition (EMT) [27-29]. Our
data showed that HPCs were in or closed to DR (Figures 2
and 3). Other authors proposed that DR is an important
source of progenitor cells that can repopulate both the bile
ductular and hepatocytic lineages in diseased liver [5,30].
HPCs expansion forms DR by provided “field-effects”
of a continuing necroinflammatory microenvironment.
They were evidenced by their location in close proximity
to the DR, and the strong correlation between these two
variables [27]. The combination of interferon-γ and
tumor necrosis factor alpha, cytokines overexpressed in
HCV (Hepatitis C virus) may inhibit primary hepatocyte
replication and stimulate HPCs expansion [31-33]. Cel-
lular signalling between HPCs and the surroundingnonparenchymal population is an important determin-
ant of HPCs behaviour [34]. Our subsequent result
showed that DR was higher in HBsAg (+) subgroup
than in HBsAg (−), which meant that HPCs in DR ex-
panded actively in HBsAg (+) (Table 2). ECM remodel-
ling, such as fibrosis resolution and laminin deposition
is likely to be important prerequisite to HPCs activation
Table 1 Necroinflammatory grade, fibrotic stage and
correlations with DR





DR 2 2-3 1-4 N.A.
Necroinflammatory
grade
9 7-12 4-15 0.563 3.4E-10
Fibrotic stage 4 3-5 1-6 0.435 3.1E-06
Correlations of DR with necroinflammatory grade and fibrotic stage were
tested using Spearman’s rho coefficients tests.
Table 2 Correlations of DR with clinicopathologic features
Variable
Age (year) (median; 25 and 75 percentiles) 50; 40-59
Gender
ALT (U/L) (median; 25 and 75 percentiles) 44.6; 29.9-72
γ-GT (U/L) (median; 25 and 75 percentiles) 74.6; 46.4-106.8
ALP (U/L) (median; 25 and 75 percentiles) 145; 116.5-190
AFP (ng/ml) (median; 25 and 75 percentiles) 325; 40.9-1000
HBsAg state




Microscopic vascular invasion (mean ± SD)* 4.3 ± 3.5
BCLC stage (A/B/C) 39/12/55
TNM stage (I/II/III) 35/23/48
Recurrence**
Chi-square tests for all the analyses. *Vascular invasion positive cases (36) were enro
**A total of 81/106 (76.4%) patients suffered from tumor recurrence, of whom 60/8
than two years after surgery.
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that HPCs, in a suitable environment, could be induced
to a direction of portal fibroblastic differentiation
through EMT [36]. Chronic carbon tetrachloride (CCl4)
administration to mice induces significant hepatic fi-
brosis and can induce a florid HPCs response in paral-
lel with advanced fibrosis [37]. It was suggested that
the HPC response may drive liver fibrogenesis rather
than being a secondary event [38].
Inflammation can supply bioactive molecules to the
tumor microenvironment, including limiting cancer cell
death [39,40]. Necrotic cell death releases proinflammatoryDR (<2 vs ≥2)
Low (%) High (%) p
≤50 13 (50.0) 43 (53.8) 0.379
>50 13 (50.0) 37 (46.2)
Male 22 (84.6) 66 (82.5) 0.534
Female 4 (15.4) 14 (17.5)
≤40 16 (61.5) 28 (35.0) 0.017
>40 10 (38.5) 52 (65.0)
≤55 13 (50.0) 24 (30.0) 0.063
>55 13 (50.0) 56 (70.0)
≤121 13 (50.0) 18 (22.5) 0.007
>121 13 (50.0) 62 (77.5)
≤20 11 (42.3) 14 (17.5) 0.010
>20 15 (57.7) 66 (82.5)
Negative 10 (38.5) 6 (7.5) 4.9E-04
Positive 16 (61.5) 74 (92.5)
≤5 7 (26.9) 28 (35.0) 0.447
>5 19 (73.1) 52 (65.0)
Single 25 (96.2) 54 (67.5) 0.004
Multiple 1 (3.8) 26 (32.5)
Yes 10 (38.5) 14 (17.5) 0.027
None 16 (61.5) 66 (82.5)
No 18 (69.2) 52 (65.0) 0.692
Yes 8 (30.8) 28 (35.0)
≤5 7 (87.5) 10 (35.7) 0.031
>5 1 (12.5) 18 (64.3)
A 16 (61.5) 23 (28.8) 0.003
B/C 10 (38.5) 57 (71.2)
I 15 (57.7) 20 (25.0) 0.002
II/III 11 (42.3) 60 (75.0)
Early 8 (47.1) 52 (65.0) 0.010
Late 9 (52.9) 12 (35.0)
lled, the degree of microscopic peritumoral vascular invasion was observed.
1 (74.1%) patients recurred within two years and 21/81 (26.0%) recurred more
Figure 4 Kaplan–Meier analysis of DR and necroinflammatory grade from original cohort. Decreased DR (A and B), decreased
necroinflammatory grade (C and D) and decreased DR with decreased necroinflammatory grade (E and F) were significantly associated with
prolonged RFS (low/low vs high/low, low/high and high/high, p = 0.013, = 0.001 and <0.001; high/low vs low/high, p = 0.858; high/low vs high/high,
p = 0.347; low/high vs high/high, p = 0.356) and OS (low/low vs high/low, low/high and high/high, p = 0.002, <0.001 and <0.001; high/low vs low/high,
p = 0.472; high/low vs high/high, p = 0.191; low/high vs high/high, p = 0.373). The median was used as cut-off of DR and necroinflammatory
grade, respectively.
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a consequence, necrotic cells can recruit inflammatory cells
of the immune system [39,41]. Additionally, necrotic cells
can release bioactive regulatory factors, such as IL-1a,
which can directly stimulate neighboring viable cells to
proliferate [39]. Incipient neoplasias and potentially inva-
sive and metastatic tumors may gain an advantage by toler-
ating some degree of necrotic cell death, doing so in order
to recruit tumor-promoting inflammatory cells that bring
growth-stimulating factors to the surviving cells within
these growths [42].
DR expressing CK perhaps contains ones deriving
from malignant degeneration of HPCs. The CK-positive
HCC cells play the leading role in directing aggressive
behavior of the tumor cell population [43]. The presence
of CK19 expression by >5% of cells in HCC is associated
with a poor prognosis [8]. The study of CK expression
in the liver provides a useful insight into the mecha-
nisms underlying progenitor cell activity and tissueregeneration following liver damage. HPCs express CK7
and CK19 [44]. They potentially derive from malignant
degeneration of HPCs. HCC expressing CK19 had a
higher incidence of AFP expression [8]. Our data showed
that increased CK19-immunoreactive DR correlated with
elevated serum AFP (Table 2). The higher recurrence rate
of CK19 (+) HCC after transplantation suggests a worse
prognosis for HCC expressing CK19 as compared to
CK19 (−) HCC [8].
There are two types of recurrence for HCC: one is early
recurrence, the other is late recurrence [21]. Discriminat-
ing between these two types is necessary in order to deter-
mine the appropriate intervention after surgery. True
metastasis would benefit from adjuvant chemotherapy,
while de novo cancer would be prevented by better control
of viral infection and/or cirrhosis [45]. Our data showed
that patients with early recurrence had significantly higher
DR compared with patients with late recurrence. Patients
with recurrence had especially higher DR and high
Table 3 Univariate and multivariate analyses of prognostic factors
Variable Overall survival Recurrence-free survival
Univariate Multivariate Univariate Multivariate
p HR (95% CI) p p HR (95% CI) p
Age, year (≤50 vs >50) 0.719 N.A. 0.881 N.A.
Gender (female vs male) 0.013 N.A. 0.003 N.A
ALT, U/L (≤40 vs >40) 0.264 N.A. 0.800 N.A.
γ-GT, U/L (≤55 vs >55) 0.030 N.A. 0.581 N.A.
ALP, U/L (≤121 vs >121) 0.007 N.A 0.077 N.A
Serum albumin, g/L (<35 vs ≥35) 0.632 N.A 0.712 N.A
AFP, ng/ml (≤20 vs >20) 0.095 N.A. 0.169 N.A.
HBsAg (negative vs positive) 0.207 N.A. 0.449 N.A.
Tumor size, cm (≤5 vs >5) 6.0E-05 2.950 (1.694-5.137) 1.3E-04 0.003 1.804 (1.057-3.080) 0.031
Tumor number (single vs multiple) 0.006 N.A. 3.3E-05 N.A.
Tumor capsule (yes vs none) 0.016 N.A. 0.015 N.A.
Microscopical intrahepatic metastasis (no vs yes) 0.165 N.A. 0.021 N.A.
Microscopic vascular invasion (no vs yes) 0.354 N.A. 0.017 N.A.
Portal vein invasion (no vs yes) 0.004 N.A. 0.348 N.A.
BCLC stage (A vs B/C) 3.3E-08 2.738 (1.602-4.679) 2.3E-04 2.2E-07 N.A.
TNM stage (I vs II /III) 1.8E-07 N.A. 3.4E-08 3.597 (2.046-6.324) 8.8E-06
Necroinflammatory grade (<9 vs ≥9) 0.001 N.A. 0.003 1.837 (1.087-3.105) 0.023
Fibrotic stage (≤4 vs >4) 0.014 N.A. 0.103 N.A.
DR (<2 vs ≥2) 2.6E-05 4.294 (2.255-8.177) 9.3E-06 4.8E-04 2.380 (1.250-4.534) 0.008
Liver ischemic time, min (≤25 vs >25) 0.760 N.A. 0.683 N.A.
Blood loss, ml (<800 vs ≥800) 0.007 N.A. 0.063 N.A.
Blood transfusion (yes vs no) 0.089 N.A. 0.071 N.A.
The median was used as cut-off of necroinflammatory grade, fibrotic stage and DR respectively. Variables with p <0.05 in univariate analysis were adopted for
multivariate analysis. Tumor size and DR were included, other covariates including tumor number, tumor capsule and portal vein invasion were then excluded.
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recurrence, indicating the importance of alleviating
necroinflammation, protecting hepatic function and
strengthening general immunity. DR correlates with
the degree of inflammation and fibrosis in the course
of many chronic human liver diseases. Inflammation
can supply bioactive molecules to the tumor micro-
environment that facilitates inductive signals that lead
to activation of EMT [39]. Some results indicated the
critical association between the metastasis and EMT
[46]. Mesenchymal stem cells in inflammation micro-
environment accelerate HCC Metastasis by Inducing
EMT [47]. DR may undergo the process of EMT in pa-
tients with the highest grade of necroinflammation
[26]. Maybe the higher peritumoral DR was the prog-
nostic indicator for early recurrence after hepatectomy
due to intrahepatic metastasis through EMT.
The lack of liver donation, highly cost of operation
and post-operative treatment, caused that few liver
transplantation was carried out in our hospital. OS rates
after hepatectomy for HCC was low. 5-yr survival afterhepatectomy for HCC was 32.1% in this series. Because
there were 71 (67%) patients with HCC whose tumor
size was more than 5 cm, and the tumor size was inde-
pendent prognostic factors for RFS and OS in our study.
On the other hand, 67 (63.2%) patients had B/C of
BCLC stage, 71 (67%) patients had II/III of TNM stage.
Our study showed that increased peritumoral DR often
correlated with multiple nodules and the absence of a
tumor capsule, which are two features of a highly invasive
HCC phenotype. Our study also showed that increased
peritumoral DR correlated with severe microscopic vascu-
lar invasion. The cases with peritumoral multiple portal
vein invasions tend to show early recurrence after hepatic
resection. That’s the reason why it is common in early re-
currence. Therefore, a very close follow-up protocol is re-
quired for patients with increased DR because it usually
reveals highly aggressive tumor behavior.
Conclusion
In conclusion, we demonstrated for the first time that peri-
tumoral DR in a necroinflammatory microenvironment is
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continuing necroinflammatory microenvironment provides
“field-effects” for stimulating HPCs expansion to form DR
and partly to be diverted to malignant direction. DR ex-
pressing CK19 perhaps contains ones deriving from malig-
nant degeneration of HPCs. Maybe the pretumoral DR is
the prognostic indicator for early recurrence after hepatec-
tomy due to intrahepatic metastasis through EMT. This
provides a rationale for anti-inflammatory, anti-EMT and
HPCs targeted therapies in clinical practice. Further exper-
iments are needed to reveal the mechanisms of DR, EMT
and inflammatory cells.
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